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Abstract
Poor adherence to pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) can lead to human immunodeficiency virus (HIV) acquisition and emergence of drug resistant infections, respectively. Measurement of antiviral drug levels provides objective adherence information that may help prevent adverse health outcomes. Gold standard drug-level measurement by liquid chromatography/mass spectrometry is centralized, heavily instrumented, and expensive and is thus unsuitable and unavailable for routine use in clinical settings. We developed the REverse TranscrIptase Chain Termination (RESTRICT) assay as a rapid and accessible measurement of drug levels indicative of long-term adherence to PrEP and ART. The assay uses designer single stranded DNA templates and intercalating fluorescent dyes to measure complementary DNA (cDNA) formation by reverse transcriptase in the presence of nucleotide reverse transcriptase inhibitor drugs. We developed a probabilistic model for the RESTRICT assay by calculating the likelihood of incorporation of inhibitors into cDNA as a function of the relative concentrations of inhibitors and nucleotides. We validated the model by carrying out the RESTRICT assay using aqueous solutions of tenofovir diphosphate (TFV-DP), a measure of long-term adherence to PrEP and ART. We used dilution in water as a simple sample preparation strategy to detect TFV-DP spiked into blood. The RESTRICT assay accurately distinguishes TFV-DP drug levels within the clinical range for adherence and has the potential to be a useful test to identify patients with poor adherence to ART and PrEP.
For nearly 40 million people living with HIV (PLHIV) and millions more at risk of acquiring HIV, 1 antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) can extend the length and quality of life and prevent HIV infection. 2 As access to ART and PrEP improves globally, adherence to medication is increasingly becoming a challenge in HIV treatment and prevention. [3] [4] [5] Poor adherence to ART among PLHIV leads to viral rebound, emergence of drug-resistant HIV, and treatment failure. 6 Poor adherence to PrEP reduces individual and community-level HIV prevention benefits. Roughly 30% of PLHIV receiving ART do not maintain sufficient adherence, [7] [8] [9] and non-adherence rates were higher in several PrEP trials. 10 Poor adherence arises for several reasons including: presence of barriers to care or medication, medication side effects, psychological problems, and poor provider-patient relationships. 11 Clinicians, patients, and patient advocates need tools to accurately assess ART and PrEP adherence to effectively implement interventions to improve adherence. 3, 12 There are several approaches for measuring ART and PrEP adherence. Subjective measures of adherence, such as self-reports and surveys, 3, 13 pill counts and tracking of pharmacy refills, 3, 4, 14 and wireless pill containers, 15, 16 do not provide proof of actual pill ingestion and have been shown to be inaccurate. 3 Digital pills with radio frequency transmitters embedded in gel caps provide proof of pill ingestion and information about short and long-term adherence patterns, 17 but require an individual to wear an RFID receiver that transmits the signal to a cloud-based server, and concerns around cost and privacy could limit acceptance by patients in global settings. 3 Quantifying concentrations of HIV drugs and their metabolites is an objective approach to measuring drug adherence. [18] [19] [20] [21] Tenofovir disoproxil fumarate (TDF) is used in all PrEP regimens currently recommended by health organizations (e.g. WHO and US Centers for Disease Control) and is also used in ~58% of all ART regimens. 22 After ingestion, TDF is hydrolyzed into tenofovir (TFV) and phosphorylated intracellularly by nucleotide kinases into tenofovir diphosphate (TFV-DP), the active form of the drug. 23 TFV-DP is a nucleotide reverse transcriptase inhibitor (NRTI) that causes DNA chain termination when HIV reverse transcriptase (HIV RT) attempts to form complementary DNA (cDNA) from a RNA template. Tenofovir has a short half-life (17 hours) and a single dose is detectable for up to 4 days in plasma and up to 7 days in urine. 23, 24 Measuring TFV as a marker of adherence is susceptible to the "white coat" effect, where one is unable to distinguish patients who take their medications regularly from those who take their medications just before a doctor's office visit. 25, 26 On the other hand, TFV-DP has a longer half-life (17 days) and provides cumulative adherence information over a 30-day period. 24, 27 TFV-DP drug levels are associated with health outcomes such as viral suppression in PLHIV, 28 efficacy of PrEP in HIV-negative people at risk of infection, 29 engagement in mental health care 20 among PLHIV, and the risk of viral rebound in PLHIV. 21 Immunoassays were recently developed to measure TFV in urine and blood. [30] [31] [32] [33] A competitive immunoassay in urine accurately classified 98% of participants in the TARGET study in Thailand who took a dose in the last 24 hours as adherent. 34 Another competitive immunoassay measuring TFV in urine was tested among PrEP participants at the FIGHT clinic in Philadelphia and distinguished low and high adherence over 48 h and also identified non-adherence that was sustained for more than 7 days before measurement. 33 All the HIV adherence monitoring immunoassays developed so far have targeted TFV and as such are susceptible to the white coat effect. 25, 32 Developing an immunoassay to detect TFV-DP is challenging since TFV and TFV-DP differ by only two phosphate groups and are both similar to intracellular molecules like adenosine monophosphate and adenosine triphosphate.
TFV-DP drug levels can be measured accurately by liquid chromatography/mass spectrometry (LC/MS). 24, 35 TFV-DP levels in peripheral blood mononuclear cells measured by LC/MS demonstrated that study participants taking ≥ 4 doses/week of PrEP were protected from HIV infection while participants taking ≤ 2 doses/week remained at significant risk of infection. 35 Castillo-Mancilla et al used LC/MS and a pharmacokinetic model to estimate TFV-DP drug levels in red blood cells (RBCs), with median concentrations ranging from 15 -170 fmol/10 6 RBCs depending on adherence. 24 Nevertheless, LC/MS requires significant capital investment, extensive sample preparation, trained personnel, and cold chain storage of reagents and is thus not readily available in clinical settings. 25 There is considerable interest in developing drug-level assays that can be implemented with minimal capital investment, equipment, and personnel, and that could readily available to physicians. 3, 4 In this paper, we develop an enzymatic assay, termed REverse TranscrIptase Chain Termination (RESTRICT), for ART and PrEP adherence monitoring. The assay takes inspiration from the mechanism of action of TFV-DP on HIV RT and infers drug levels by measuring the length of cDNA generated by RT in the presence of DNA building blocks. Enzyme inhibition assays targeting RT were originally developed in the context of HIV detection, [40] [41] [42] enzyme characterization, [39] [40] [41] [42] drug screening, [43] [44] [45] and drug resistance monitoring. 43, 44, [46] [47] [48] Although enzyme inhibition assays have been used to evaluate the effectiveness of reverse transcription inhibitors and new drug candidates, [43] [44] [45] to our knowledge such assays have not been applied to measure drug adherence. One reason for this may be that pharmacokinetic data about drug levels corresponding to ART and PrEP adherence were only recently investigated and reported. 24, 27 We formulate a probabilistic model to guide assay design and validate the model with TFV-DP spiked in buffer and blood at clinically relevant concentrations.
THEORETICAL MODEL
We developed a theoretical model to measure drug concentration using the principles of the RESTRICT assay ( Figure 1) , The assay requires a nucleic acid template, a primer, free nucleotides (dNTPs), NRTIs (e.g. TFV-DP), intercalating dye, and RT enzyme. RT forms double-stranded DNA (dsDNA) by polymerizing a chain of free nucleotides complementary to a nucleic acid template starting from a region of the template that is hybridized to a primer. At low NRTI concentrations relative to dNTP concentration (scenario A in Figure 1 ), RT is unlikely to incorporate NRTIs into the cDNA chain and can polymerize the ssDNA into full-length dsDNA strands that bind to many intercalating dye molecules and provide a high assay signal. Conversely, at high NRTI concentrations (scenario C in Figure 1 ), RT is very likely to incorporate TFV-DP into the cDNA chain early, resulting in chain termination and formation of short DNA fragments that bind to fewer intercalating dye molecules and provide a low assay signal. At moderate levels of NRTI (scenario B in Figure 1 ), the length of the dsDNA product varies and follows a sigmoidal relationship characteristic of enzyme inhibition reactions as shown in Figure 1 . In this way, the fluorescence readout from the RESTRICT assay is used to distinguish between low, medium, and high NRTI concentrations. We used DNA templates in the RESTRICT assay because they are less expensive and more stable than RNA templates. It is important to note that although the RESTRICT assay targets the reverse transcriptase (RT) enzyme, our choice to work with DNA rather than RNA templates means that we do not target the reverse transcription function of the enzyme. Instead, the RESTRICT assay targets the DNA polymerization function of RT enzyme. Nevertheless, the polymerization function of the RT enzyme is also inhibited by NRTIs because of the promiscuity of the RT enzyme in incorporating nucleotide analogs during cDNA formation and its poor error correction capabilities. 49 
Fluorescence from full-length dsDNA products
As illustrated in Figure 1 , fluorescence at the end of the RESTRICT assay depends on the interaction between intercalating dye and full-length dsDNA ( Figure 1A ), dsDNA fragments ( Figure 1B) , and unpolymerized ssDNA template ( Figure 1C ). The fluorescence from full-length dsDNA products, "# , depends on the probability of completion of full-length dsDNA, the length of the DNA template, and the fluorescence properties of the intercalating dye, and can be expressed as,
where dNTP is the probability that dNTP is inserted into all successive chain termination sites in the cDNA chain, is the length of a full-length dsDNA product, dye is a constant that represents the fluorescence per double-stranded base pair per unit concentration provided by the intercalating dye, and &'(# is the concentration of DNA template in the assay. In this model, is the number of base-pairs in the entire, full-length dsDNA product, where corresponds to the total number of bases where NRTI could be inserted (i.e. number of bases complementary to the NRTI in the template strand) and is always less than . Both and depend on the exact sequence of the nucleic acid template used in the RESTRICT assay.
We assume that the assay is operating at steady state and that dNTP and NRTIs are not depleted during the assay. In addition, we assume that the probability that dNTP is inserted into each of the available NRTI insertion sites in a DNA template is an independent event. Thus, the probability of formation of full-length dsDNA, dNTP , is the probability of a series of n successive dNTP incorporation events which can be calculated using the multiplicative rule for probabilities as,
aff is the relative affinity of RT for an NRTI compared to its native dNTP substrate, [
] is the concentration of NRTI, and [ ] is the concentration of dNTP present in the assay.
Combining equations (1) and (2), we can express the fluorescence from full-length dsDNA as,
Fluorescence from fragment dsDNA products
Double stranded DNA fragments also contribute to the total fluorescence at the end of the RESTRICT assay ( Figure 1 ). Similar to full-length DNA, the fluorescence from dsDNA fragments depends on the probability of formation of a fragment and the length of the DNA fragment. At a given dNTP concentration and NRTI concentration, we can calculate the probability of chain termination at any of the possible insertion sites for NRTI in the DNA template. Given that a dsDNA fragment is formed whenever there is an NRTI insertion event, we can calculate the probability of formation of each fragment as,
The index counts the bases where it is possible to insert NRTI and the maximum value of is the total number of NRTI insertion bases, or simply . +/01,RSH is the probability that dNTP is incorporated in the nucleic acid template at all bases preceding base in the template at which NRTI is inserted and can be calculated using equation 3, /T0U is the probability of NRTI insertion into the nucleic acid template resulting in chain termination and is simply the probability that NRTI is inserted instead of dNTP and expressed as,
Note that +/01,3YH and /T0U are constants for any experimental condition since they represent the probabilities of single insertion events for either dNTP or NRTI, and we assume that we are working in a regime where reagent depletion is not a concern.
We can calculate the probability of formation of fragments of sizes ranging from 1 bp to − 1 bp, where is the total number of available NRTI insertion bases in the DNA template. Given the probabilistic nature of dNTP and NRTI insertion, we expect that there is a distribution of dsDNA fragments sizes at each pair of dNTP and NRTI concentrations. To determine the total fluorescence contribution from dsDNA fragments, we calculate the sum of the fluorescence from all the different dsDNA fragment sizes.
Adapting equation (3) and summing the fluorescence from individual dsDNA fragments, the fluorescence from dsDNA fragments can be expressed as follows,
Where ( ) is the length of the dsDNA fragment when it is terminated at base and can be deduced from the exact sequence of the DNA template.
Fluorescence from unpolymerized ssDNA template
We also account for the fluorescence contribution of intercalating dye interacting with unpolymerized nucleic acid template. At high NRTI concentrations, very little (if any)
dsDNA is formed and most of the fluorescence output comes from interactions between the intercalating dye and the unpolymerized ssDNA template ( Figure 1C ). Intercalating dyes produce a measurable fluorescence signal when bound to ssDNA fragments. For example, PicoGreen dye used in our experiments, provides 11 times more fluorescence when bound to dsDNA compared to ssDNA. 50, 51 Each dsDNA fragment has a corresponding ssDNA fragment with length equal to the difference between the total length of the nucleic acid template and the dsDNA fragment. Thus, the fluorescence from the ssDNA fragments can be calculated as,
By combining equations (1) - (7) we can calculate the total fluorescence of the RESTRICT assay as,
To develop this probabilistic model, we assumed that the assay operates at steady state and that dNTP and NRTI are not limiting reagents in the reaction. For example, the increase in output fluorescence from full-length product as the template concentration increases that is predicted in equation (2) 
EXPERIMENTAL SECTION RT activity assays
We first determined optimal assay conditions for RT activity in order to minimize assay time and the reagent concentration and cost required. RT Data was analyzed using GraphPad Prism 8.1 software (GraphPad Software Inc.). The fluorescence intensity from the RT activity assay as a function of time was fit to an exponential curve. RT activity data as a function of RT concentration was fit to a fourparameter logistic regression curve that follows the familiar symmetrical sigmoidal shape of enzymatic assays. The four-parameter logistic curve fits take the form:
For RT activity assays, represented the fluorescence intensity while represented the enzyme concentration.
RESTRICT assay in buffer
After determining assay times as well as enzyme and reagent concentrations required for measurable RT activity, we carried out inhibition assays with TFV-DP (166403-66 depending on the experimental conditions tested (see Table S1 in the supplementary information). Serial dilutions of TFV-DP in buffer spanning a concentration range of 1 -10,000 nM were prepared to generate curves representative of TFV-DP inhibition.
Assay characterization experiments were carried out at final dNTP concentrations of 300, 1560, and 6250 nM. Assays were stopped by adding PicoGreen and readout with the plate reader as described earlier.
Fluorescence from RESTRICT assay data was normalized to allow comparison of data points gathered at different dNTP concentrations. Normalization was carried out as,
where the subscripts max and min denote the maximum and minimum measured fluorescence values from each inhibition curve. RESTRICT assay data were fit to four-parameter logistic regression curves that follow the familiar symmetrical sigmoidal shape of enzymatic assays. The 50% inhibition concentration (IC50) -the concentration of the drug required to achieve 50% inhibition of its target enzyme in vitro was obtained using equation 9 where the parameter is the TFV-DP concentration and the parameter represents the IC50. The IC50 is often used as a metric to evaluate inhibitor potency and to assess how the position of the inhibition curve shifts (whether lower or higher) when assay conditions (e.g. substrate concentration) are modified. 55 To compare experimental data and theory, empirical values were derived for the constants C"" and +,' (see equation 3). C"" was chosen by calculating IC50 values from experiments and theory at 300, 1560, and 6250 nM of dNTP. C"" was varied from 0 to 1 in increments of 0.05. We chose a C"" value that ensured that the experimental and theoretical IC50 values differed by < 20% at all dNTP concentrations tested. +,'
was calculated by multiplying the calculated fluorescence from the theory by the ratio of the maximum fluorescence from the experimental data to the maximum fluorescence from the calculated theory.
RT activity assays in diluted blood
HIV-negative, human whole (BioIVT, Westbury, NY) was diluted in nuclease-free water (3098, Sigma) to lyse RBCs and reduce unwanted inhibition of RT activity by blood components such as immunoglobulins. Blood was mixed with the water by vortexing and incubated for 5 minutes to ensure that the RBCs were lysed. Serial dilutions of blood in water were carried out to make solutions that had final blood concentrations ranging from 2% to 10.0%. 5 µL of diluted whole blood at each final concentration was added to 35 µL of master mix to conduct RT activity assays at 500 nM dNTP. Assays were stopped by adding PicoGreen and read out with the plate reader. Baseline correction was carried out by subtracting the average fluorescence from negative controls (with no RT enzyme and no blood) from the fluorescence obtained from each of the RT activity assays.
RESTRICT assays in diluted whole blood
We performed RESTRICT assays using blood spiked with TFV-DP. Master mixes for the RESTRICT assay with TFV-DP spiked in 2% blood consisted of final concentrations of 2 nM DNA template, 20 nM primer, 100 nM dNTP, 100 nM of HIV-1 RT, and a range of TFV-DP concentrations. We prepared serial dilutions of TFV-DP in diluted blood to correspond with a concentration range of 5.7 -11,000 fmol/10 6 RBCs in whole blood, and thus cover the clinical range for TFV-DP adherence measurement (see Table S2 in the supplementary information). 5 µL of solutions containing TFV-DP spiked in 2% blood were added to 35 µL of master mix so that the final concentration of blood in the RESTRICT assay was 0.25%. Data corresponding to high and low TFV-DP concentrations within the clinical range for adherence measurement were compared using an unpaired t-test in GraphPad Prism.
RESULTS & DISCUSSION
The RESTRICT assay measures the average length of cDNA synthesized by RT enzyme in the presence of TFV-DP. To demonstrate the utility of this assay for adherence measurement, we first characterized RT activity to ensure that we operated in a regime that provided high assay signal in the absence of TFV-DP. We determined enzyme and reagent concentrations and assay incubation time required for high RT activity. We developed a probabilistic model for the RESTRICT assay and validated this model with experimental data obtained with TFV-DP spiked in aqueous buffer and showed good agreement between experimental data and theory at a wide range of dNTP and TFV-DP concentrations. Finally, we demonstrated that the assay could measure TFV-DP spiked in blood at clinically relevant concentrations.
RT activity characterization
To characterize RT activity, we first determined the effect of RT concentration and assay time on the rate of cDNA production as measured by the output fluorescence of an RT activity assay. Figure 2A the assay for so long that there is a risk of reagent depletion that might skew inhibition measurements. Working at roughly half the time to plateau in an enzyme activity assay typically provides strong measurable signals over background levels and accurate enzyme inhibition measurements. 55 Thus, we chose a 30 min incubation time for our assay because it provided strong signals over background levels. In addition, the short assay time would also potentially allow for quick (same day) turnaround of adherence measurements to patients and clinicians.
To further characterize the effect of RT concentration on assay output signal, we measured the fluorescence intensity at 8 different concentrations of RT enzyme with assay time and reagent concentration held constant. Given that RT is the most expensive reagent used in the inhibition assay, our goal was to determine an RT concentration that provided a strong measurable signal over background levels, while also minimizing the RT concentration required for the assay. Figure 2B plots the endpoint assay fluorescence intensity versus 8 RT concentrations ranging from 3.1 to 400 nM. The fluorescence intensity remains at the same level as the negative control (no RT) until ~25 nM RT when it begins to increase significantly, and then plateaus above ~200 nM RT. We chose 100 nM RT as the concentration used in inhibition assays because it provides a large and consistent signal over background levels without using excess RT. 
Template concentration (nM) Fluorescence Intensity (a.u)
background Furthermore, we measured the fluorescence output as a function of DNA template concentration to determine the lowest template concentration and dNTP concentration at which we could measure fluorescence with the plate reader. Figure 2C 
RESTRICT assays in buffer
We performed assays with TFV-DP spiked in aqueous buffer. Serial dilutions of TFV-DP in buffer spanning a concentration range of 1 -10,000 nM were prepared to obtain inhibition curves. This concentration range covers two orders of magnitude above and below the clinically-relevant concentration range for TFV-DP adherence described in pharmacokinetic studies. 24, 27 Using the model and the experiments we determined +,' = 2.03 × 10 HI as the fluorescence per double-stranded base pair per unit concentration provided by the intercalating dye and C"" = 0.50 as the relative affinity of RT for TFV-DP compared to its native dNTP substrate. Figure 3A shows experimental data and theory of the fluorescence from the RESTRICT assay. The data shows the typical sigmoidal-shaped curves representative of enzyme inhibition assays as a function of TFV-DP concentration. In both the experimental data and the theory in Figure 3A , the fluorescence intensity decreases with dNTP concentration. This decrease occurs because we keep the ratio of dNTP and DNA template concentrations constant, to prevent dNTP depletion. Equations 1, 6, and 7
show that the fluorescence from full-product DNA, fragment DNA, and unpolymerized DNA template are directly proportional to the DNA template concentration. RESTRICT assays with serial dilutions of TFV-DP at different dNTP concentrations (shown in the legend).
Fluorescence intensity increases with dNTP concentration. Lines show fluorescence intensity calculated using the theory in Equations (1) to (7) . We normalized the experimental data and theoretical calculations to more clearly visualize the effect of dNTP concentration on the position of the inhibition curves relative to the clinical range for TFV-DP adherence measurement. Figure 3B shows normalized endpoint RESTRICT assay fluorescence from experiments and theory. In both experiment and theory, as dNTP concentration increases the inhibition curves shift right, towards higher TFV-DP IC50 values. Figure 3C shows the measured IC50 values as a function of dNTP concentration along with a linear fit of IC50 values from theory. IC50 values increase linearly as a function of dNTP concentration. Figure 3B shows that the normalized experimental data is in better agreement with the model than the raw fluorescence data. This is because the model predicts the IC50 and response shape more accurately than it predicts end-point fluorescence, which depends on small variations in assay conditions and the plate reader response.
Using the theory described in equations (1) to (7) and the relationship between dNTP and IC50 in Figure 3C , we can design a RESTRICT assay with an IC50 value that enables us to differentiate TFV-DP concentrations that correspond to different adherence levels. To decrease the IC50, the dNTP and template concentration must decrease; however, there are limits to the relationship between IC50 and dNTP described in Figure 3C . For example, as the dNTP concentration is decreased to obtained lower IC50 values, template concentration must also be decreased to avoid dNTP depletion. Thus, at lower dNTP concentrations and corresponding lower template concentrations, the fluorescence intensity decreases (see Figure 3A ). Thus, we can only decrease dNTP concentration until we run into the lower limit of detection of the fluorescence reader (see Figure 2C ).
RT activity assay in blood
TFV-DP accumulates intracellularly in both red blood cells and white blood cells. We chose to target TFV-DP in red blood cells because red blood cells are more abundant and are easier to lyse in order to release TFV-DP. As reported extensively in reverse transcription and DNA amplification assays, blood matrix components, such as immunoglobulins, inhibit RT activity and require sample preparation when working with whole blood. [56] [57] [58] Autofluorescence from blood components 59 can also obscure the signal from the RESTRICT assay.
We chose dilution in water as a simple and user-friendly strategy for sample preparation 60 because it both lyses red blood cells and also reduces the concentration of blood matrix components thereby accomplishing our goals of simulating TFV-DP detection in a clinically relevant matrix and reducing unwanted suppression of reverse transcriptase activity. 60, 61 We tested various dilutions of whole blood in water to determine how much dilution was required to minimize non-specific inhibition. Figure 4A shows characterization of RT activity in diluted blood. The net fluorescence intensity, i.e. the difference between fluorescence from each RT activity assay with spiked blood and the background signal from no RT enzyme controls at each blood dilution, decreases as blood fraction increases and is indistinguishable from the background at 1.88% final concentration of blood. There is only a 20% decrease in fluorescence intensity compared to positive control (RT in buffer) at 0.25% final concentration of blood. Figure   4A shows that the non-specific inhibition of RT enzyme by blood matrix components also decreases with the concentration of blood in the assay.
To perform RESTRICT assays in blood, we chose a blood dilution that reduces nonspecific RT inhibition using Figure 4A . We also chose a dNTP concentration at which to run the assay to ensure that the clinical range of the assay overlapped with the linear region of the inhibition curve. There is a tradeoff between blood dilution and the required analytical sensitivity of the assay. Although greater blood dilution reduces non-specific inhibition of RT enzyme by blood matrix components ( Figure 4A ), greater dilution also decreases the available amount of analyte (TFV-DP) in blood. Figures 3B and 3C show that the inhibition curve is shifted to lower TFV-DP concentrations by decreasing dNTP concentration. Figure 2C shows that the lowest template concentration and the lowest dNTP concentration at which we could detect RT activity in buffer was 0.25 nM template and 25 nM dNTP respectively. Anticipating that RT activity in blood would be more variable than in buffer, we re-ran RT activity assays in diluted blood to determine the lowest dNTP concentration at which we could perform RT activity assays. We chose a final concentration of 0.25% blood (dilution factor 400x) to minimize non-specific inhibition. Final Blood Concentration (%) Net Fluorescence (a.u) pos ctrl -buffer only, no blood C difference between the fluorescence measured from each data point minus the signal from a "no RT enzyme" control at the same conditions. This ensures that any variations in background signal from introducing diluted blood into the assay are accounted for. Figure 4B shows that there is a measurable fluorescence signal at 25 nM dNTP in buffer that increases gradually as the dNTP concentration is increased to 50 nM and 100 nM, consistent with Figure 2C . Conversely, the variation in RT activity when 0.25% blood is introduced means that the net fluorescence is zero at both 25 nM and 50 nM dNTP and a measurable signal from RT activity in 0.25% blood is only measurable at 100 nM. Thus, we determined that the lowest dNTP concentration that we could work with in 0.25% whole blood was 100 nM.
RESTRICT assay in blood
Using the data in Figures 4A and 4B , we designed a RESTRICT assay for semiquantitative measurement of clinically relevant TFV-DP concentrations spiked in diluted whole blood. Figure 4C shows data from an inhibition curve with 0.25% blood, 100 nM dNTP, at various TFV-DP concentrations around the clinical range for adherence measurement. We see the characteristic sigmoidal shape indicative of enzyme inhibition reactions.
We compared the normalized fluorescence intensities from the inhibition assay at low and high TFV-DP concentrations within the clinical range to determine whether we could distinguish concentrations that correspond to low and high adherence with statistical confidence. As shown in Table 1 , the p-value is 0.013 for the unpaired t-test comparing fluorescence at 16.9 fmol/10 6 RBCs TFV-DP, corresponding to low adherence, with the fluorescence at 152.3 fmol/10 6 RBCs TFV-DP, indicating high adherence. These data demonstrate that the RESTRICT assay accurately distinguishes TFV-DP drug levels in spiked blood with high statistical confidence. 
SUMMARY
In this paper, we present RESTRICT -an enzymatic assay for measurement of long-term PrEP and ART adherence. The assay measures cDNA formation by RT in the presence of TFV-DP. At high TFV-DP concentrations, cDNA chain termination occurs resulting in lower fluorescence signals from intercalating dye. We develop a probabilistic model for the RESTRICT assay by considering the likelihood of incorporation of TFV-DP into cDNA as a function of the relative concentrations of TFV-DP and dNTP. We show that decreasing dNTP concentration shifts RT inhibition curves to lower TFV-DP concentrations. The data and model show that there is a linear relationship between dNTP concentration and IC50 values. We spiked TFV-DP into hemolyzed whole blood and measured RT inhibition at TFV-DP concentrations within the clinical range for adherence measurement to demonstrate that the assay can operate in clinically relevant samples. The assay distinguished TFV-DP concentrations corresponding to low and high adherence suggesting that in future it might be a useful test to identify patients at risk of treatment failure.
Compared with ART and PrEP adherence monitoring by measuring TFV levels in urine, the RESTRICT assay measures TFV-DP and provides a longer-term measurement that is not susceptible to the white coat effect, where patients take their medications just before a doctor's office visit. The RESTRICT assay can measure TFV-DP quickly, with less sample preparation, and capital investment than by LC/MS. The described assay gives measurable results within an hour whereas TFV-DP measurement by LC/MS requires several hours for sample processing and analysis and results are often not available for weeks because samples must be sent to one of the few centralized labs capable of measuring TFV-DP.
The RESTRICT assay has few liquid handling steps and relies on reagents and equipment (e.g. microplate reader and pipettes) that are commonly used and readily available in many clinical and biochemical laboratories. In addition, the cost per test is low since small reagent volumes (40 µL master mix) are required. The assay could be performed using fingerprick samples since < 5 µL of blood is required per assay and previous studies have established correlations between HIV drug metabolites in venous and fingerprick blood draws. 62 The RESTRICT assay has the potential to be further integrated into a near-patient test for use in a doctor's office or a patient's home by replacing the microplate reader with a portable and inexpensive fluorescence reader or mobile phone 63, 64 and thus be a critical tool for preventing HIV transmission and drug resistance. We envision a test where assay reagents are lyophilized and stored in a tube or cartridge and the assay is initiated by adding blood and dilution buffer, incubating, and reading out results in a simple instrument.
The assay has some limitations that might preclude its use in particular contexts. For example, the assay does not yet distinguish between inhibition by NRTIs like TFV-DP and inhibition by non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz that are sometimes included in ART regimens. For example, a patient may appear adherent if they took a recent dose of NNRTIs. This limitation is not a concern in PrEP clients since NNRTIs are not used in PrEP. Furthermore, as first line ART regimens in most of low-and middle-income countries switch from NNRTIs to dolutegravir (an integrase inhibitor), 65 this limitation might not be a long-term concern.
The assay needs to be validated with clinical samples and benchmarked against drug level measurements by LC/MS. This work is innovative because it develops a new category of adherence measurement test that could allow patients and clinicians to monitor and improve long-term ART and PrEP adherence and healthcare outcomes.
SUPPORTING INFORMATION
Tables providing further additional details on the experimental conditions (master mix preparation for RESTRICT assays and TFV-DP dilutions in blood) are provided in the supplementary information.
